Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1GF
|
|||
| Former ID |
DCL000265
|
|||
| Drug Name |
XL880
|
|||
| Synonyms |
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72] | Phase 2 | [2], [3] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 2 | [2], [3] | ||
| Squamous head and neck cell carcinom [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 2 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Exelixis; GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H34F2N4O6
|
|||
| Canonical SMILES |
COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
|
|||
| InChI |
1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
|
|||
| InChIKey |
CXQHYVUVSFXTMY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 849217-64-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
81082087, 86465340, 93375504, 99436987, 104246801, 123055389, 124490358, 124757009, 125163814, 125329934, 126731542, 131480687, 134338922, 134964398, 135257201, 135727454, 136367309, 136367948, 136920382, 137245315, 137275745, 137275948, 137760554, 143499560, 144115968, 152043738, 152234432, 152258182, 152344218, 160647018, 162011882, 162037444, 162196274, 163348564, 164041883, 170501826, 172913907, 174530915, 177748909, 178102306, 185997073, 185998158, 186000980, 188899550, 198948852, 198993146, 223387910, 223704673, 224083490, 226703719
|
|||
| ChEBI ID |
CHEBI:91418
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01147484) A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197). U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679). | |||
| REF 3 | Clinical pipeline report, company report or official report of Exelixis (2011). | |||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.